Results from Pivotal Trials in Low Back Pain and Post-Surgical Pain SAN ANTONIO, May 4 /PRNewswire/ -- Endo Pharmaceuticals Inc. announced data from pivotal studies of oxymorphone extended-release (ER ...
Initial Data Suggests Oxymorphone Immediate-Release Effective for Acute Pediatric Postoperative Pain
BALTIMORE, Md.—Oxymorphone immediate-release is generally well tolerated in children, but a single dose ≤10 mg may not provide analgesia for up to 6 hours in some patients, results from the first part ...
(Reuters) - The U.S. Food and Drug Administration on Friday denied Endo Health Solutions' petition to block generic forms of its widely abused prescription pain drug Opana ER, a surprise decision by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results